BUZZ - Molson Coors shares fall after lowering annual performance expectations
路透社2026/11/05 13:06November 5 - ** Molson Coors Beverage Company (TAP.N) shares fell 2.9% to $41.89 in pre-market trading
** The beer maker now expects net sales in 2026, at constant currency, to decline by 1% to 2%, as opposed to the previous expectation of a range from 1% growth to a 1% decline
** Its forecast for basic earnings per share (EPS) decline for the current fiscal year has been raised from the previous estimate of 11%-15% to 16%-19%
** Attributed to global macroeconomic impacts and consumer behavior
** The company stated that the trend of weak global beer sales in the second and third quarters will continue in the fourth quarter
** Net sales and adjusted earnings per share in the third quarter both missed expectations
** As of the close of the previous trading day, TAP had declined approximately 8% year-to-date
(To facilitate non-native English speakers, Reuters provides its reports automatically translated into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of these translated texts and provides them solely for reader convenience. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.